Fairvalue-Calculator Fairvalue-Calculator
EN DE

SillaJen, Inc (215600) Fair Value & Analysis

Healthcare · KR · Market cap 358B KRW

Price2,415 KRW
Fair Value3,588 KRW
Upside+48.6%
Quality95/100
Evidence: Low Range 2,691 KRW – 4,484 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SillaJen, Inc (215600) currently trades at 2,415 KRW, while our model-based Fair Value estimate is 3,588 KRW — implying the stock looks roughly 48.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is SillaJen, Inc (215600) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 3,588 KRW versus a price of 2,415 KRW — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 215600?
Our 21-model fair value for SillaJen, Inc is 3,588 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 2,415 KRW.
What is the quality score of 215600?
SillaJen, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.